5 research outputs found
Automatic thermal model identification and distributed optimisation for load shifting in city quarters
Buildings with floor heating or thermally activated building structures offer significant potential for shifting the thermal load and thus reduce peak demand for heating or cooling. This potential can be realised with the help of model predictive control (MPC) methods, provided that sufficiently descriptive mathematical models of the thermal characteristics of the individual thermal zones exist. Creating these by hand is infeasible for larger numbers of zones; instead, they must be identified automatically based on measurement data. In this paper an approach is presented that allows automatically identifying thermal models usable in MPC. The results show that the identified zone models are sufficiently accurate for the use in an MPC, with a mean average error below for the prediction of the zone temperatures. The identified zone models are then used in a distributed optimisation scheme that coordinates the individual zones and buildings of a city quarter to best support an energy hub by flattening the overall load profile. In a preliminary simulation study carried out for buildings with floor heating, the operating costs for heating in a winter month were reduced by approximately 9%. Therefore, it can be concluded that the proposed approach has a clear economic benefit
Optimal operation of residential heating systems with logwood boiler, buffer storage and solar thermal collector
Diagnostic evaluation and treatment recommendations for dogs with substage-a high-grade multicentric lymphoma: results of a survey of veterinarians
Sphingolipids in neutrophil function and inflammatory responses: Mechanisms and implications for intestinal immunity and inflammation in ulcerative colitis
Empagliflozin in Patients with Chronic Kidney Disease
Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo